Dermatologic Principles and Practice in Oncology. Conditions of the Skin, Hair, and Nails in Cancer Patients
- Language: English
- 440 Pages
- Published: January 2014
- Region: Global
In the Psoriasis Thought Leader Panel #25 2013-12, seven experts (6 derms, 1 rheum; 4 US, 4 EU) in the treatment of moderate/severe psoriasis and moderate/severe psoriatic arthritis share their year--end views on the strengths and weaknesses of key competitors in development for these indications.
A note on color--coding in this report. Blue font in the report reflects comments made by Thought Leaders interviewed in October/November 2013. Green font reflects comments made by Panelists who were interviewed in the Spring of 2013.
Psoriasis often appears between the ages of 15 and 25, but can develop at any age. Psoriatic arthritis usually develops between the ages of 30 and 50. Coupling these age of onset statistics with the experience that patients cycle through antipsoriatic therapy on average each 18--24 months, one realizes that there will be room for many new competitors in this space.
However, most of our thought leaders say that they will try two therapies from a class before moving on to a new mechanism of action. This tempers the commercial opportunity for the 3rd, 4th and 5th competitor unless there is a significant benefit to the patient, physician or payer. For the patient, there is a new paradigm: reaching PASI 100 is an attainable goal for more than 50% of patients with moderate / severe psoriasis (see IL17 inhibitors). For the physician, "methotrexate without monitoring" offers a safe, easy to manage therapy (apremilast) for more moderate cases. For payers, biosimilar versions of etanercept (in the EU) and adalimumab (worldwide) are imminent.
Against this backdrop the panel talks about the most recent trial data for the following mechanisms of action and molecules:
- TNF: adalimumab, etanercept, golimumab, certolizumab, ABP-501, PF-06410293, CT-P13, CHS- 0214
- IL23: ustekinumab, tildrakizumab, guselkumab, BI-655066
- IL17: brodalumab, secukinumab, ixekizumab
- IL17 / TNF: ABT-122
- JAK: tofacitinib, baricitinib, GSK2586184, INCB039110, ASP015k, PF-04965842, ABT494
- PDE4: apremilast
- IL6: clazakizumab
- Fumarate: XP-23829, LAS-41008
- Innate Immunity SHOW LESS READ MORE >
For full table of contents please download free sample.